Hepatitis C and Porphyria Cutanea Tarda

Joseph C. English, Mark F. Peake, Larry E. Becker

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Porphyria cutanea tarda (PCT) is a clinical manifestation of decreased uroporphyrinogen decarboxylase (UPD) activity. Multiple endogenous and exogenous factors have been implicated in inducing PCT in genetically predisposed patients. The most recent is the RNA virus hepatitis C (HCV), which is transmitted via blood exposure. The mechanism of action in HCV-induced PCT is unknown but produces the same clinical, laboratory, and histopathologic changes seen in other forms of sporadic PCT. Therefore, patients presenting with PCT clinically should be tested serologically for antibodies against HCV and patients with HCV should be monitored for signs and symptoms of PCT.

Original languageEnglish (US)
Pages (from-to)404-408
Number of pages5
JournalCutis
Volume57
Issue number6
StatePublished - Dec 1 1996
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Hepatitis C and Porphyria Cutanea Tarda'. Together they form a unique fingerprint.

Cite this